Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Basic science

6258 - Defining the lethal subclone in metastatic lung cancer


20 Oct 2018


Proffered paper session - Basic science


Translational Research

Tumour Site


Mariam Jamal-Hanjani


M. Jamal-Hanjani1, A. Huebner1, N. McGranahan1, C. Swanton2

Author affiliations

  • 1 University College London Cancer Institute, Cancer Research UK Lung Cancer Centre of Excellence, WC1E 6BT - London/GB
  • 2 Translational Cancer Therapeutics, The Francis Crick Institute, NW1 1AT - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6258


The PEACE study aims to study the genetic and phenotypic relationships between primary and metastatic tumours to establish a model for tumour progression, the metastatic process and potential mechanisms involved in therapeutic resistance and tumour evolution.


In a cohort of patients initially recruited into the lung TRACERx study (NCT01888601), multiregion sampling was performed at each site of metastasis, DNA was extracted from fresh frozen tissue and deep whole-exome sequencing (WES) was subsequently performed and analysed using bioinformatic tools developed to assess tumour clonal architecture (Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(22):2109-2121).


Preliminary analysis of the first four TRACERx/PEACE patients has demonstrated the presence of driver events, including mutations and somatic copy number aberrations, in both early and late evolution, continued tumour diversification driving genome instability, and different patterns of metastatic seeding. Using evolutionary phylogenetic analyses, the timing of such events is demonstrated from primary to metastatic disease.


PEACE has the potential to inform our understanding of the metastatic process and to reveal the lethal subclone (s) that are involved in branched tumour evolution. The study has recruited over 100 patients and involved over 50 tissue harvests to date. Data arising from PEACE has already demonstrated implications for tracking disease progression (Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451), the emergence of drug resistance and identifying distinct patterns of metastatic spread with prognostic implications (Turajlic S, Xu H, Litchfield K, et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. 2018;173(3):581–594.e12). WES data from primary and metastatic tumours in this cohort of patients recruited into both TRACERx and PEACE can help decipher the clonal dynamics and evolutionary trajectory of lung cancer. This is a unique study leveraging the true longitudinal sampling in these studies from diagnosis to death.

Clinical trial identification

PEACE (PosthumousEvaluation of Advanced Cancer Environment, NCT03004755)

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.